A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This trial is a 52-week safety study to evaluate the safety of adjunctive aripiprazole in
outpatients with major depressive disorder who have experienced an incomplete response to an
ongoing antidepressant trial.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.